Abingdon Health PLC · LSE:ABDX
Abingdon Health — Investor Presentation (March 2024)
12 slides from Abingdon Health's investor presentation, March 2024
Slide 1: Investor Presentation
Investor Presentation Chris Yates, CEO March 2024
Slide 2: Contents
Contents 1. Overview 2. Investment Case 3. Interim Results Highlights 4. Focused Strategy 5. Looking Forward 6. Summary 7. Q&A IMPROVING LIFE BY MAKING R APID TESTING ACCESSIBLE TO ALL 2
Slide 3: Overview
Overview WHO WE ARE WHAT WE DO • Founded in 2008, headquartered in York, UK PRODUCTS • Dedicated lateral flow CRO & CDMO • Dedicated lateral flow CRO & CDMO • Offering a range of additional services: regulatory, • 84 employees analytical laboratory service & clinical trial support, packaging design
Slide 4: Investment Case
Investment Case ● Focused on the Lateral Flow market which is large and growing: ▪ $23bn market forecast (2027): product mix changing ▪ COVID-19 widespread use of lateral flow has reduced barriers to adoption ▪ Technology is simple, cost-effective, easy-to-use ▪ Supports decentralisation of testing
Slide 5: Focused Strategy
Focused Strategy Lateral Broaden and Self-testing Expand range Flow CRO & deepen service lateral flow sales and reach CDMO offering & distribution 1 2 3 4 • Lateral flow experts • Grow customer base • Range of 15 self-tests under the • Abingdon Simply Test will be • CRO & CDMO service Abingdon Simpl
Slide 6: Interim Results: H1 2024 Operational Highlights
Interim Results: H1 2024 Operational Highlights Focused Lateral Flow CRO & CDMO service provider Company’s full-service offering resonating well with customers across a range of industries Solid traction across all contract service areas; with a number of projects transitioning through from developm
Slide 7: Interim Results: H1 2024 Financial Highlights
Interim Results: H1 2024 Financial Highlights Revenue of £2.4m for H1 2024 (H1 2022: £1.1m) with growth rate of 117% compared with H1 2023 H2 2024 revenue is expected to be significantly improved compared with H1 2024. FY 2024 revenues are expected to be materially higher than FY 2023 revenues Again
Slide 8: Project Pipeline Growth
Project Pipeline Growth As at 1 January 2023 14 Live Projects Human Development D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 Animal Transfer T12 T13 T14 Food, Environmental, Plant Regulatory As at 13 March 2024 30 Live Projects Development D1 D2 D3 D4 D5 D6 D8 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17 Transfer T1
Slide 9: Case Study: Long-Term partnership approach
Case Study: Long-Term partnership approach 1 2 3 4 5 2019- 2019 2019 2019 2023 2024 ▪ First project ▪ Product licensed by ▪ Abingdon ▪ Continued product ▪ Abingdon commenced with customer to major commences manufacturing commences technical Customer A to multinational manufacturing for growth transf
Slide 10: Looking Forward
Looking Forward ● Continued growth in CRO and CDMO customer base across contract development, TT, manufacturing & regulatory ● Over time transition of customers to (long-term) manufacturing customers – Salignostics, LoopDx, UpFront. Others to follow in H2 2023/4 ● Continue to broaden service proposi
Slide 11: Summary
Summary 1 Dedicated lateral flow CRO/CDMO, recognised LFT knowledge leader 2 Large & growing lateral flow market driven by reduced barriers to adoption post-COVID-19 3 Paradigm shift in testing away from lab and into home, clinic, farm or field…. 4 H1 2023/4: 117% like-for-like revenue growth. Cash
Slide 12: Q&A
Q&A IMPROVING LIFE BY MAKING R APID TESTING ACCESSIBLE TO ALL